Pegaspargaza
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 130167-69-0 |
| ATC kod | L01XX24 |
| DrugBank | DB00059 |
| Hemijski podaci | |
| Formula | ? |
| Mol. masa | 0,000 |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intramaskularno, intravenozno |
Pegaspargaza (Oncaspar) je modifikovani enzim, koji se koristi kao antineoplastični agens. On je forma L-asparaginaze na kojoj je izvršena pegilacija.[1][2][3]
Ovaj lek se koristi u tretmanu akutne limfocitne leukemije.[4][5]
- ↑ Graham ML: Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302. PMID 14499708
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- ↑ Graham ML (2003). „Pegaspargase: a review of clinical studies”. Adv. Drug Deliv. Rev. 55 (10): 1293–302. DOI:10.1016/S0169-409X(03)00110-8. PMID 14499708.
- ↑ Patel SS, Benfield P (Jun 1996). „New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)”. Clinical Immunotherapeutics 5 (6): 492–496.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
